Exploration of novel biomarkers for hypertensive disorders of pregnancy by comprehensive analysis of peptide fragments in blood: their potential and technologies supporting quantification-Reference-Cited by-同舟云学术

Exploration of novel biomarkers for hypertensive disorders of pregnancy by comprehensive analysis of peptide fragments in blood: their potential and technologies supporting quantification

Published:2021-10-19 Issue:1 Volume:60 Page:44-51
ISSN:1434-6621
Container-title:Clinical Chemistry and Laboratory Medicine (CCLM)
language:en
Short-container-title:

Author:

Araki Yoshihiko¹²³^ORCID,Miura Yoshiki⁴,Fujiwara Hiroshi⁵

Affiliation:

1. Institute for Environmental & Gender-Specific Medicine, Juntendo University Graduate School of Medicine , Chiba , Japan

2. Department of Obstetrics & Gynecology , Juntendo University Graduate School of Medicine , Tokyo , Japan

3. Department of Pathology and Microbiology , Division of Microbiology and Immunology, Nihon University School of Medicine , Tokyo , Japan

4. Laboratory of Proteomics & Biomolecular Science , Research Support Center, Juntendo University Graduate School of Medicine , Tokyo , Japan

5. Department of Obstetrics & Gynecology , Kanazawa University Graduate School of Medical Sciences , Ishikawa , Japan

Abstract

Abstract Among the many complications associated with pregnancy, hypertensive disorders of pregnancy (HDP) constitute one of the most important. Since the pathophysiology of HDP is complex, new disease biomarkers (DBMs) are needed to serve as indicators of disease activity. However, in the current status of laboratory medicine, despite the fact that blood pressure measurement has been used for a long time, not many DBMs contribute adequately to the subsequent diagnosis and treatment. In this article, we discuss studies focusing on peptide fragments in blood identified by comprehensive quantitative methods, among the currently proposed DBM candidates. Furthermore, we describe the basic techniques of peptidomics, especially quantitative proteomics, and outline the current status and challenges of measuring peptides in blood as DBM for HDP.

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry (medical),Clinical Biochemistry,General Medicine

Link

https://www.degruyter.com/document/doi/10.1515/cclm-2021-0713/pdf

Reference39 articles.

1. Nelson-Piercy, C, de Swiet, M, Lewis, G. Medical deaths in pregnancy. Clin Med 2008;8:11–2. https://doi.org/10.7861/clinmedicine.8-1-11.

2. de Swiet, M. Maternal mortality in the developed world: lessons from the UK confidential enquiry. Obstet Med 2008;1:7–10. https://doi.org/10.1258/om.2008.080020.

3. von Dadelszen, P, Payne, B, Li, J, Ansermino, JM, Broughton Pipkin, F, Côté, AM, et al.. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011;377:219–27. https://doi.org/10.1016/s0140-6736(10)61351-7.

4. Brown, MA, Magee, LA, Kenny, LC, Karumanchi, SA, McCarthy, FP, Saito, S, et al.. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24–43. https://doi.org/10.1161/hypertensionaha.117.10803.

5. Sutton, ALM, Harper, LM, Tita, ATN. Hypertensive disorders in pregnancy. Obstet Gynecol Clin N Am 2018;45:333–47. https://doi.org/10.1016/j.ogc.2018.01.012.